


An Insight into the Sex Differences in COVID-19 Patients: What are the Possible Causes?

Parisa Maleki Dana;¹ Fatemeh Sadoughi;¹ Jamal Hallajzadeh;²  Zatollah Asemi;¹ Mohammad Ali Mansournia;³ Bahman Yousefi;^{4,5} Mansooreh Momen-Heravi^{6,7}

1. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran
2. Department of Biochemistry and Nutrition, Research Center for Evidence-Based Health Management, Maragheh University of Medical Sciences, Maragheh, Iran
3. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5. Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
6. Department of Infectious Disease, school of medicine, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran
7. Infections Diseases Research Center, Kashan University of Medical Sciences, Kashan, Islamic Republic of Iran

Correspondence:

Zatollah Asemi, PhD
 Research Center for Biochemistry and Nutrition in Metabolic Diseases
 Institute for Basic Sciences
 Kashan University of Medical Sciences
 Kashan, Islamic Republic of Iran
 E-mail: asemi_r@yahoo.com
 Jamal Hallajzadeh
 Department of Biochemistry and Nutrition
 Research Center for Evidence-Based Health Management
 Maragheh University of Medical Sciences
 Maragheh, Iran
 E-mail: jamal.hallaj@yahoo.com

Conflicts of interest: The authors declare no conflict of interest.

Keywords: ACE2; COVID-19; estrogen; gender; sex differences; sex hormones; testosterone

Abstract

Studies have reported a sex bias in case fatalities of COVID-19 patients. Moreover, it is observed that men have a higher risk of developing a severe form of the disease compared to women, highlighting the importance of disaggregated data of male and female COVID-19 patients. On the other hand, other factors (eg, hormonal levels and immune functions) also need to be addressed due to the effects of sex differences on the outcomes of COVID-19 patients. An insight into the underlying causes of sex differences in COVID-19 patients may provide an opportunity for better care of the patients or prevention of the disease. The current study reviews the reports concerning with the sex differences in COVID-19 patients. It is explained how sex can affect angiotensin converting enzyme-2 (ACE2), that is a key component for the pathogenesis of COVID-19, and summarized the gender differences in immune responses and how sex hormones are involved in immune processes. Furthermore, the available data about the impact of sex hormones on the immune functions of COVID-19 cases are looked into.

Maleki Dana P, Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, Yousefi B, Momen-Heravi M. An insight into the sex differences in COVID-19 patients: what are the possible causes? *Prehosp Disaster Med.* 2020;35(4):438–441.

Sex Differences and COVID-19

Several studies have shown that there is an association between the sex of COVID-19 patients and fatality rates, as well as critically-ill status. Studies in China, South Korea, United States, and Italy have reported a similar trend of sex bias in fatality rates of COVID-19 patients, representing that case fatality rates are higher in male patients than in female patients.^{1–3} Noteworthy, the same findings have reported in the previous outbreaks of coronaviruses, Severe Acute Respiratory Syndrome (SARS), and the Middle East Respiratory Syndrome (MERS).^{4,5} Moreover, studies performed on mice have shown that males are more susceptible to coronaviruses.⁶ The likelihood of death is reported to be 65% higher in male patients with COVID-19 than in women. The World Health Organization (WHO; Geneva, Switzerland) indicated that a lower percentage of women who are infected

Abbreviations:

ACE2: angiotensin converting enzyme-2
 ADAM-17: ADAM metalloproteinase domain-17
 AR: androgen receptor
 CCL: chemokine (C-C motif) ligand
 cFT: calculated free testosterone
 CRP: C-reactive protein
 CXCL: chemokine (C-X-C motif) ligand
 E2: estradiol
 ESR: estrogen receptor
 ICU: intensive care unit
 IL: interleukin
 mACE2: myocardial angiotensin converting enzyme-2
 NHBE: normal human bronchial epithelial
 RICU: respiratory intensive care unit
 sACE2: soluble angiotensin converting enzyme-2
 SARS: Severe Acute Respiratory Syndrome

SARS-CoV: Severe Acute Respiratory Syndrome Coronavirus
 TMPRSS2: transmembrane serine protease-2
 TT: total testosterone

Received: May 23, 2020

Revised: June 4, 2020

Accepted: June 10, 2020

doi:[10.1017/S1049023X20000837](https://doi.org/10.1017/S1049023X20000837)

© The Author(s), 2020. Published by Cambridge University Press on behalf of World Association for Disaster and Emergency Medicine. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

with the virus will die in comparison with men (1.7%/2.8%). Another investigation also reported that less female patients needed intensive care or died compared to male patients (15%/32%).⁷ In 43 hospitalized patients, women were significantly less prone to develop the severe form of the disease.⁸ Jin, et al⁸ expressed that male patients' deaths in a population of 37 cases were 2.4-times that of female patients. Moreover, they concluded that men's worse outcomes and higher deaths compared to women is not dependent on age.⁸ In a retrospective study of 168 confirmed patients with COVID-19, deaths occurred in 12.8% of men (n = 11/86); meanwhile, 7.3% of women died (n = 6/82).⁹ It is observed that there are differences in laboratory parameters of men and women, including neutrophil/lymphocyte ratio, hemato-crit, hemoglobin, ferritin, alanine aminotransferase, aspartate aminotransferase, total bilirubin, C-reactive protein (CRP), blood urea nitrogen, and creatinine (all P values <.05). Moreover, male patients with comorbidities had a higher risk of developing a critically-ill status compared with men without comorbidities; whereas, there was no such association in women.⁹ Evidence suggested that female patients experienced some COVID-19 symptoms significantly more than male patients, such as fatigue, anosmia, headache, sore throat, and nasal obstruction.¹⁰ Moreover, some symptoms were experienced significantly more by men than women, including cough and fever. However, it is reported that there was no difference regarding disease duration between men and women.¹⁰ Borghesi, et al³ also reported that in COVID-19 patients aged between 50 to 79 years old, men had a significantly higher score of chest x-ray scoring system than women.

Besides the different effects of COVID-19 on the physical status of men and women, studies have shown that the same goes for mental health of people. Studies of general population indicated that women present more mental disorders symptoms compared to men during the COVID-19 pandemic, including signs of depression, anxiety, post-traumatic stress symptoms, and decreased sleep quality.^{11,12} In the viewpoint of health care workers, evidence shows that COVID-19 has affected the mental health of female medical staff more than men.¹³ Altogether, this information highlights the importance of disaggregated data of male and female COVID-19 patients. An insight into the underlying causes of sex differences in COVID-19 patients may provide an opportunity for better care of the patients or prevention of the disease. Additionally, attention should be paid to other factors which are or may be related to this sex bias in fatality rates of COVID-19 patients, including hormonal levels, immune functions, comorbidities, and related conditions, as well as gender-related factors, including lifestyle and socioeconomic aspects.¹⁴

Possible Underlying Causes of Sex Differences in COVID-19 Patients

Sex Differences in Inflammatory Processes

Since X-chromosome encodes some genes related to immune responses, women have a lower level of viral load and less inflammation compared to men. Women's immune cells activate more than men, which is associated with the stimulation of toll-like receptor-7 and interferon production. Besides, after infection with viral agents, women produce lower levels of interleukin-6 (IL-6) compared to men, which is associated with better longevity.¹⁵ Plasma concentration of testosterone, which decreases with age, is reported to be reduced by some comorbidities, such as diabetes, obesity, and obstructive sleep apnea.¹⁶ Evidence has shown that these comorbidities are common in patients with COVID-19.

Investigations have indicated that aging men have a reduced testosterone level, which is related to an elevated pro-inflammatory condition.¹⁷ Besides, it is observed that testosterone therapy leads to a reduction in IL-6, IL-1 β , and tumor necrosis factor α (TNF- α).¹⁸ Therefore, Pozzilli, et al¹⁹ proposed that through the activation of cytokine storm, testosterone may be involved in the progression of COVID-19. Androgen receptor (AR) is involved in the regulation of both innate and adaptive immune responses, including the macrophage and neutrophil recruitment which is related to COVID-19.²⁰⁻²² In mice infected with a respiratory virus, estrogen receptor (ESR) signaling is reported to increase the morbidity and mortality. While this observation applies to both sexes, estrogen therapy has resulted in the suppression of inflammatory processes and reduction of virus titers in animal models.²³ Estrogen enhances immune responses and subsequently, pathogens clearance occurs faster and vaccines will be more effective. Contrary to estrogen, testosterone plays inhibitory roles in immune processes, which is a possible explanation for men's higher susceptibility to infections.²⁴ Thus, sex hormones' alterations may cause some changes in the immune response to pathogen, indicating the role of some other relevant conditions, such as pregnancy and hormone therapies in COVID-19.¹⁴

In a cohort study of 31 male COVID-19 patients, data demonstrated that patients who were transferred to intensive care unit (ICU) or died in respiratory ICU (RICU) had lower amounts of total testosterone (TT) and calculated free testosterone (cFT) compared to patients who were transferred to internal medicine unit or were at a stable condition in RICU.²⁵ The TT and cFT levels were negatively associated with some risk factors, including lactic dehydrogenase, procalcitonin, and neutrophil count. However, the levels of TT and cFT were positively associated with the lymphocyte count. Furthermore, TT had a negative correlation with the amounts of CRP and ferritin.²⁵ Fagone, et al²⁶ observed that in age group of 40 to 60 years, the transcriptomic characteristics of female lung tissue has more similarities to COVID-19-induced characteristics compared to male tissue. A possible explanation of the lower incidence of COVID-19 in female patients could be the lower threshold of acute immune response to COVID-19 in men compared to women. The AR regulates two chemotactic factors, the chemokine (C-X-C motif) ligand-1 (CXCL1) and chemokine (C-C motif) ligand-20 (CCL20), which are encoded by COVID-19-induced genes. The ESR1 regulates C3 and endothelin-1, which are also encoded by COVID-19-induced genes.²⁶ Fagone, et al²⁶ suggested that while CXCL1 and CCL20 are involved in different infections of coronavirus, response to these infections are occurred by different agent in men and women. Moreover, it is shown higher mortality rates in female mice with SARS coronavirus (SARS-CoV) who were treated by the antagonist of ESR in comparison with their counterparts who were treated with vehicle.²⁷

Angiotensin-Converting Enzyme-2 (ACE2) Differences in Men and Women

Angiotensin-converting enzyme-2 (ACE2) is an essential component for the entrance of COVID-19 to the cells.^{28,29} Since ACE2 gene is located on X-chromosome, women have the potential to be heterozygous regarding this enzyme while men are homozygous.⁷ To priming spike protein, COVID-19 also requires the transmembrane serine protease-2 (TMPRSS2).^{30,31} The TMPRSS2 is the only critical protease for the pathogenesis and viral spread of SARS-CoV.³² While TMPRSS2 gene transcription depends on the activity of AR, there is no other promotor to do the same

function in humans.³³ It is suggested that testosterone may lead to male predominance of severe infections (eg, COVID-19) through modulating the expression of TMPRSS2.³⁴ In the other hand, TMPRSS2 is the most common gene involved in primary prostate cancer, indicating that administering inhibitors of TMPRSS2, which are currently used for prostate cancer, may be helpful for treatment or prevention of COVID-19.^{33,35,36} The ACE2 may be cleaved by TMPRSS2, leading to an enhancement in the entry of the virus.³⁷ Interestingly, rebalancing of ACE1/ACE2 or high levels of ACE2 possibly enhances the COVID-19 outcomes in both males and females through reducing thrombosis, inflammation, and death.⁷

ADAM metalloproteinase domain-17 (ADAM-17), which is a disintegrin and metalloproteinase-17, leads to the soluble ACE2 (sACE2) and shedding of SARS-CoV through the cleavage of myocardial ACE2 (mACE2).^{38,39} Evidence has revealed that both sexes have the same levels of sACE2 up to the age of 12. However, its levels increase in boys with their growth and women have a lower level of sACE2 than men from the age of 15.⁴⁰ As evidenced by Sward, et al,⁴⁰ cases with higher sACE2 (men>women) may have a greater risk of severe COVID-19. It is shown that ACE2 over-expression has led to the severity of SARS-CoV disease in mice.⁴¹ Studies also indicated that high activities of mACE2 and/or ADAM-17 may be involved in the severity of COVID-19.^{38,41} Contrary to the globally observed data, female rats with higher expression of ACE2 are reported to have poorer prognosis.⁷ Stelzig, et al⁶ reported that normal human bronchial epithelial (NHBE) cells that were treated with 17 β -estradiol (E2) had a lower expression level of ACE2 messenger ribonucleic acid (mRNA) compared with NHBE cells that were treated with the vehicle, ethanol. Experimental animal studies have indicated that in kidney and adipose tissue, E2 enhances the activity and expression of ACE2.⁴² Noteworthy, precautions should be observed in testosterone therapy, especially in men with hypogonadism, due to the recent evidence of venous thromboembolism in COVID-19 patients.⁴²

Limitations

However, this study has some limitations. First of all, not all published papers are in English, and thus had to be excluded from this review. Another limitation that was faced was the inconsistency of existing data from COVID-19 patients. Besides, a significant number of studies concerning COVID-19 have not reported the disaggregated data of men and women due to the urgent need for rapid publications of the research. Furthermore, findings in this area are limited and there are not many large-scale studies reporting the sex differences in COVID-19 patients and the reason for this difference. Thus, further studies are required to draw a conclusion.

Conclusions

Studies of COVID-19 patients have shown that men have a higher risk of developing to the severe form of the disease compared to women. Moreover, case fatalities are higher in male patients than female patients. Therefore, more attention should be paid to sex as an important variable. By reviewing the literature about the sex differences in COVID-19, it can be concluded that some sex-related factors are involved in determining the patients' outcomes. This study shows that different levels of ACE2 in men and women, the effects of testosterone on ACE2 levels, and the fact that the ACE2 gene is located on the X-chromosome should not be ignored. Furthermore, the effects of sex on immune responses and data available on the sex differences in COVID-19 patients and immune system are summarized. However, findings in this area are limited and further studies are required to draw a conclusion.

Author Contributions

PMD and ZA contributed in conception, design, and drafting of the manuscript. FS, JH, MAM, BY, and MMH contributed in reviewing relevant literature. All authors approved the final version for submission.

References

- Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091.
- Dudley JP, Lee NT. Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea. *Clin Infect Dis*. 2020. Epub ahead of print.
- Borghesi A, Zigliani A, Masciullo R, et al. Radiographic severity index in COVID-19 pneumonia: relationship to age and sex in 783 Italian patients. *Radiol Med*. 2020;125(5):461–644.
- Alghamdi IG, Hussain, II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med*. 2014;7:417–423.
- Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? *Am J Epidemiol*. 2004;159(3):229–231.
- Stelzig KE, Canepa-Escaro F, Schiliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2020;318(6):L1280–L1281.
- Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? *Int J Mol Sci*. 2020;21(10):E3474.
- Jin JM, Bai P, He W, et al. Gender differences in patients with COVID-19: focus on severity and mortality. *Front Public Health*. 2020;8:152.
- Meng Y, Wu P, Lu W, et al. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. *PLoS Pathog*. 2020;16(4):e1008520.
- Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med*. 2020. Epub ahead of print.
- Liu N, Zhang F, Wei C, et al. Prevalence and predictors of PTSD during COVID-19 outbreak in China hardest-hit areas: gender differences matter. *Psychiatry Res*. 2020;287:112921.
- Wang C, Pan R, Wan X, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. *Int J Environ Res Public Health*. 2020;17(5):1729.
- Pappa S, Ntella V, Giannakas T, Giannakoulis VG, Papoutsis E, Katsaounou P. Prevalence of depression, anxiety, and insomnia among healthcare workers during the COVID-19 pandemic: a systematic review and meta-analysis. *Brain Behav Immun*. 2020. Epub ahead of print.
- Spagnolo PA, Manson JE, Joffe H. Sex and gender differences in health: what the COVID-19 pandemic can teach us. *Ann Intern Med*. 2020. Epub ahead of print.
- Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. *J Biol Regul Homeost Agents*. 2020;34(2).
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2018;103(5):1715–1744.
- Maggio M, Basaria S, Ceda GP, et al. The relationship between testosterone and molecular markers of inflammation in older men. *J Endocrinol Invest*. 2005;28(11 Suppl):116–119.
- Mohamad NV, Wong SK, Wan Hasan WN, et al. The relationship between circulating testosterone and inflammatory cytokines in men. *Aging Male*. 2019;22(2):129–140.

19. Pozzilli P, Lenzi A. Commentary: testosterone, a key hormone in the context of COVID-19 pandemic. *Metabolism*. 2020. Epub ahead of print.
20. Lai JJ, Lai KP, Zeng W, Chuang KH, Altuwajri S, Chang C. Androgen receptor influences on body defense system via modulation of innate and adaptive immune systems: lessons from conditional AR knockout mice. *Am J Pathol*. 2012;181(5):1504–1512.
21. Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. *Front Immunol*. 2018;9:794.
22. Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. *Clin Immunol*. 2020. Epub ahead of print.
23. Suba Z. Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. *J Pharm Sci*. 2020;23(1):75–85.
24. Bartz D, Chitnis T, Kaiser UB, et al. Clinical advances in sex- and gender-informed medicine to improve the health of all: a review. *JAMA Intern Med*. 2020. Epub ahead of print.
25. Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. *Andrology*. 2020. Epub ahead of print.
26. Fagone P, Ciarleo R, Lombardo SD, et al. Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. *Autoimmun Rev*. 2020;19(7):102571.
27. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. *J Immunol*. 2017;198(10):4046–4053.
28. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. *Science*. 2005;309(5742):1864–1868.
29. Li W, Zhang C, Sui J, et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO J*. 2005;24(8):1634–1643.
30. Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J Virol*. 2011;85(9):4122–4134.
31. Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease *TMPRSS2*. *J Virol*. 2010;84(24):12658–12664.
32. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and *TMPRSS2* and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271–280.
33. Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease *TMPRSS2* activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. *Cancer Discov*. 2014;4(11):1310–1325.
34. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. *TMPRSS2* and COVID-19: serendipity or opportunity for intervention? *Cancer Discov*. 2020;10(6):779–782.
35. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and *TMPRSS2* and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271–280.
36. Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and *TMPRSS2* are primarily expressed in bronchial transient secretory cells. *EMBO J*. 2020;39(10):e105114.
37. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. *TMPRSS2* and *ADAM17* cleave ACE2 differentially and only proteolysis by *TMPRSS2* augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. *J Virol*. 2014;88(2):1293–1307.
38. Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. *Proc Natl Acad Sci U S A*. 2008;105(22):7809–7814.
39. Patel VB, Clarke N, Wang Z, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. *J Mol Cell Cardiol*. 2014;66:167–176.
40. Sward P, Edsfeldt A, Reepalu A, Jehpsson L, Rosengren BE, Karlsson MK. Age and sex differences in soluble ACE2 may give insights for COVID-19. *Crit Care*. 2020;24(1):221.
41. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. 2020;46(4):586–590.
42. La Vignera S, Cannarella R, Condorelli RA, Torre F, Aversa A, Calogero AE. Sex-specific SARS-CoV-2 mortality: among hormone-modulated ACE2 expression, risk of venous thromboembolism and hypovitaminosis D. *Int J Mol Sci*. 2020;21(8):2948.